Evidence map›Paper›PMID 20454799›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2010

Nasopharyngeal carcinoma in a south European population: epidemiological data and clinical aspects in Portugal.

Breda Eduardo, Catarino Raquel, Medeiros Rui

Abstract read
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Integrated genomic analysis suggests MLL3 is a novel candidate susceptibility gene for familial nasopharyngeal carcinoma.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2015
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Breda EduardoOtorhinolaryngology Department, Portuguese Institute of Oncology, R. Dr. Ant. Bernardino Almeida, Porto, 4200-072, Portugal. erbreda@gmail.com
Catarino Raquel
Medeiros Rui
Fernando Pessoa University · PTInstitute of Biomedical Science · GBInstituto Português de Oncologia Francisco Gentil · PT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The incidence of nasopharyngeal carcinoma (NPC) varies worldwide, with higher rates in southern Asia, intermediate rates in Mediterranean basin countries as well as in Greenland and Alaska populations, and low rates in most of the western countries. The percentage of NPC types seems to vary according to the WHO classification. Portugal is also a Mediterranean basin country. The NPC patterns in Portuguese population is comparatively analyzed with a review of the related literature, concerning the overall incidence, male/female ratio, age of incidence, WHO type frequency, Epstein-Barr virus relationship and genetic susceptibility. The particular findings in the Portuguese population can be discussed in the light of genetic background and close relationships with potential exogenous oncogenic factors.

Indexed as

AdultAgedAntineoplastic AgentsCarcinomaFemaleHumansIncidenceMaleMiddle AgedNasopharyngeal NeoplasmsNeoplasm StagingPortugalRisk FactorsSurvival RateAntineoplastic Agents

Identifiers

PMID20454799
OpenAlexW2095865227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.